Method of Treatment of Cancer Using Guanosine 3', 5' Cyclic Monophosphate (Cyclic GMP)
AssigneeUniversity of South Florida
InventorDavid Vesely
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of South Florida
InventorDavid Vesely
Estimating the term…
A method of treating cancer through use of guanosine 3′,5′-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 μM), 84% (1 mM), 31% (1 μM), and 30% (1 μM), respectively. Cyclic GMP decreases DNA synthesis in human pancreatic, breast, and prostate adenocarcinomas as well as small-cell and squamous cell carcinomas of the lung at its 1 μM concentration by 51%, 54%, 56%, 50% and 52%, respectively. Cyclic GMP when infused for one week decreases the tumor volume of human pancreatic adenocarcinomas in athymic mice 95% compared to untreated animals with human pancreatic adenocarcinomas.
A method of modulating the growth of cancer cells comprising the step of contacting at least one target cell with an effective amount of at least one intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone.
A method of inhibiting the growth of cancer cells comprising the steps of:
A method of inhibiting the growth of cancer cells comprising the steps of:
A method of inhibiting the growth of cancer cells comprising the steps of:
Dependencies are inferred from the claim text.